Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zukhruf Salami has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-Target In Silico Evaluation of Bioactive Phytocompounds from Irvingia gabonensis Seeds Against Oncogenic Proteins: A Computational Drug Discovery Perspective

    by Yusuf Jimoh, Hayder Raed Fadhil, Zukhruf Salami, Abdullahi Ahmad

    Cancer remains a leading cause of mortality in sub-Saharan Africa, with limited access to targeted therapies driving demand for affordable, novel lead compounds. Irvingia gabonensis (Aubry-Lecomte ex O’Rorke) Baill., known as ogbono or African bush mango, is a nutritional staple across West and Central Africa whose seed harbours bioactive phytochemicals. Molecular docking studies were conducted using AutoDock Vina (version 1.2.0) against three oncogenic targets: Bcl-2 (PDB: 6O0K), phosphoinositide 3-kinase gamma (PI3K-gamma; PDB: 1E8X), and the nuclear factor kappa-B p65 subunit (NF-kB p65; PDB: 2RAM). Five phytocompounds, namely ellagic acid, quercetin, kaempferol, lupeol, and beta-sitosterol, were evaluated alongside three reference drugs: venetoclax, idelalisib, and BAY 11-7082. Pharmacokinetic profiling was assessed through Lipinski, Veber, and Ghose drug-likeness filters, and ADMET properties were predicted using computational descriptors. Quercetin exhibited the highest binding affinity among phytocompounds, recording −9.1 kcal/mol against PI3K-gamma and −8.9 kcal/mol against Bcl-2, approaching reference idelalisib (−9.8 kcal/mol). Kaempferol and ellagic acid demonstrated consistent multi-target engagement across all three proteins. Four of five phytocompounds satisfied Lipinski criteria with zero or one violation. ADMET analysis revealed favourable safety profiles relative to reference drugs, with no predicted hERG inhibition or hepatotoxicity across phytocompounds. The phytocompound matrix of I. gabonensis seeds constitutes a computationally validated multi-target oncological scaffold. Quercetin and kaempferol emerge as the most promising phytocompounds for further experimental investigation. This study provides a reproducible computational framework and advances the case for repositioning an African food crop as a natural product lead in cancer drug discovery.

  • Open Access

    Multi-Target In Silico Evaluation of New 2-Pyrazolines as Antimicrobial Agents

    by Zukhruf Salami, Asmau Hamza, Abdullahi Idris, Yusuf Jimoh

    The world today is being ravaged by the emergence and re-emergence of microbial infections caused by antimicrobial-resistant strains, brought about primarily by the frequent and perhaps unnecessary use of antimicrobial agents. A need therefore arises to develop new antimicrobial drugs that can combat these pathogens resistant to currently available antibiotics. This present study has adopted a multi-enzyme in silico approach in evaluating new 2-pyrazolines as antimicrobial agents, targeting and aiming to inhibit three pivotal enzymes in the bacteria’s life cycle. A library of 2-pyrazolines was tailored to achieve the desired activity. The library of compounds and amoxicillin, a standard antimicrobial drug, were docked into the molecular target enzymes. They were also subjected to toxicity and drug-likeness tests, using PROTOX and swissADME, respectively. A moderate toxicity profile was indicated, as more than 90% of the ligands were in ProTox class 4. The majority exhibited advantageous ADME characteristics. A significant number of them demonstrated a binding affinity for the target proteins that was stronger than both the native ligand and the binding affinity of amoxicillin. Ligands 30, 20, and 8 are the notable ones across all target enzymes. These results suggest that these novel ligands may be powerful inhibitors, particularly when it comes to interfering with the formation of bacterial cell walls, folic acid, and nucleotide metabolism. Additional in vivo and in vitro research is required to confirm these results and evaluate their therapeutic potential.

  • Open Access

    In Silico Evaluation of Novel 2-Pyrazoline Carboxamide Derivatives as Potential Protease Inhibitors Against Plasmodium Parasites

    by Yusuf Jimoh, Idris Yunusa Abdullah, Asmau Nasir Hamza, Maryam Abdullahi, Jibril Ahmadu, Lukman Ali Hassan, Muhammad Shamsudeen Yakubu, Zukhruf Salami

    Malaria, a devastating disease caused by Plasmodium parasites, continues to pose a significant threat to global health, with increasing resistance to current antimalarial drugs. In this study, we employed an in silico approach to design and evaluate novel 2-pyrazoline carboxamide derivatives as potential protease inhibitors against Plasmodium falciparum. Our results show that all the designed ligands exhibit good drug-like properties, satisfying Lipinski’s rule of five, and have low toxicity profiles. Molecular docking studies revealed that five newly designed ligands (P5, P6, P7, P11, and P13) exhibit promising binding affinities and interactions with key protease enzymes involved in the hemoglobin degradation pathway, including Falcipain-2, Falcipain-3, and Plasmepsin-2 with PDB (Protein Data Bank) codes of 6JW9, 3BWK, and 1LF3, respectively. Notably, ligand P13 showed the strongest binding affinity with Falcipain-2, forming an additional hydrogen bond with CYS42, an essential residue for the enzyme’s catalytic activity. The interactions between the ligands and the enzymes suggest a competitive inhibition mechanism, with the potential to disrupt the hemoglobin degradation pathway and halt the parasite’s lifecycle. The biological implications of these findings are significant, as they suggest that these novel ligands could be effective against Plasmodium parasites, particularly in the context of increasing resistance to current antimalarial drugs. Overall, this study provides valuable insights into the potential of novel 2-pyrazoline carboxamide derivatives to serve as protease inhibitors against Plasmodium parasites, highlights their potential as a promising strategy for antimalarial drug development, and demonstrates the importance of in silico approaches in the discovery of novel therapeutics.